- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | Nuclear Matrix Protein 22 (NMP22) ELISA Kit |
| Catalog No. | TMTR-HMM-0070 |
| Description | A quantitative enzyme immunoassay for the detection of NMP22 in voided urine specimens, supporting bladder cancer screening and surveillance applications. |
| Intended Use | Quantitative urinary NMP22 measurement as an adjunct test for bladder cancer screening in high-risk populations and monitoring for disease recurrence. |
| Principle / Technology | Sandwich ELISA with two monoclonal antibodies recognizing distinct epitopes on the nuclear mitotic apparatus protein (NuMA), which is released into urine from apoptotic urothelial cells. |
| Detection Method | Colorimetric measurement at 450 nm |
| Sample Type | Voided urine; first morning specimen is not recommended; mid-stream collection is preferred |
| Performance Range / Specifications | 0.5–250 U/mL |
| Sensitivity / LOD | ≤0.3 U/mL |
| Specificity | Specific for the NuMA/NMP22 complex; no cross-reactivity with other urinary proteins found at milligram/mL concentrations |
| Reaction Conditions / Protocol | Two-hour protocol with sample and detection antibody co-incubation |
| Components / Formulation | Anti-NMP22 antibody-coated 96-well plate, NMP22 standard (6 concentrations), detection antibody, enzyme conjugate, TMB substrate, stop solution, wash buffer |
| Storage Conditions | 2–8°C; reconstituted standards at -20°C |
| Shelf Life | 12 months |
| Package Specifications | 96 tests |
| Product Form | Pre-coated plate |
| Quality Control | Intra-assay CV below 6%; inter-assay CV below 9% |
| Key Features | Non-invasive urine-based test for bladder cancer; suitable for point-of-care adaptation; complements cystoscopy in surveillance protocols |
For research use only, not for clinical use.
|
There is no product in your cart. |
Copyright © 2026 Alta DiagnoTech. All rights reserved.
